Valuation: Edesa Biotech, Inc.

Market Cap 34.72M 30.97M 28.7M 26.1M 48.97M 3.3B 49.75M 344M 135M 1.72B 130M 128M 5.51B P/E 2026 *
-1.4x
P/E 2027 * -1.35x
Enterprise Value 34.72M 30.97M 28.7M 26.1M 48.97M 3.3B 49.75M 344M 135M 1.72B 130M 128M 5.51B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.45%
Yield 2026 *
-
Yield 2027 * -
1 day+8.17%
1 week-20.80%
Current month-33.97%
1 month-32.85%
3 months-57.88%
6 months-53.12%
Current year+95.77%
1 week 2.52
Extreme 2.52
3.09
1 month 2.52
Extreme 2.52
4.27
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
62.65
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 2015-07-31
Director of Finance/CFO 57 2025-04-30
President 48 2019-06-06
Director TitleAgeSince
Chairman 50 2019-06-06
Director/Board Member 55 2019-06-06
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Free

Founder

6,893 0.0510%
9/1/26 Free

Founder

5,714 0.0593%
8/3/26 Free

Founder

5,324 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
+8.17%-20.80%+17.93%-32.20% 34.72M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+7.17%+10.77%+77.89% 51.2B
+0.30%+0.19%+2.53%+56.14% 51.19B
-0.38%+2.31%+29.98%+40.71% 43.93B
+0.30%+4.43%+16.99%+120.94% 41.96B
+2.35%-4.01%+236.69%+497.21% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+3.97%+21.34%+22.33% 22.5B
Average +1.66%-2.55%+44.39%+91.19% 37.24B
Weighted average by Cap. +0.97%+0.04%+46.03%+106.35%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.63M -14.49M -13.17M -24.71M -1.66B -25.11M -174M -68.22M -869M -65.76M -64.37M -2.78B -23.88M -21.29M -19.74M -17.94M -33.67M -2.27B -34.21M -237M -92.95M -1.18B -89.6M -87.7M -3.79B
Net Debt - -
Projected Income Statement - Annual - Edesa Biotech, Inc.
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
26-10-19 $2.780 +8.17% 24,767
26-10-16 $2.570 -3.75% 64,031
26-10-15 $2.670 +0.75% 75,822
26-10-14 $2.650 -6.85% 72,593
26-10-13 $2.845 -3.23% 61,373
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Edesa Biotech, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.780USD
Average target price
16.33USD
Spread / Average Target
+487.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Edesa Biotech, Inc.
  1. Stock Market
  2. Stocks
  3. EDSA Stock